Previously submitted to: JMIR AI (no longer under consideration since Feb 25, 2026)
Date Submitted: Feb 21, 2026
Open Peer Review Period: Feb 25, 2026 - Feb 25, 2026
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
The Universal BioCode Framework: A Philosophical-Numerical Integration of Multi-Omic Data, Digital Pathology, and Clinical Outcomes in 33 Cancer Types and 500,000+ Population Cohort
ABSTRACT
Background:
Background:
Despite advances in genomics, proteomics, and digital pathology, precision medicine remains fragmented across data types and clinical contexts. No universal framework exists to integrate multi-omic data, pathological imaging, and clinical outcomes into a cohesive predictive model.
Objective:
To develop and validate a philosophical-numerical framework (BioCode) based on AquaNumerica codes (3, 7, 12) that integrates multi-omic data, digital pathology, and clinical outcomes into a single predictive model for precision medicine.
Methods:
We analyzed 11,057 cancer patients from The Cancer Genome Atlas (TCGA; 33 cancer types), 1,026 patients from the Clinical Proteomic Tumor Analysis Consortium (CPTAC), 30,247 digital pathology images from The Cancer Imaging Archive (TCIA), and 502,413 individuals from UK Biobank. Data were normalized using ComBat to remove batch effects and integrated into a unified matrix based on three cardinal codes: Code 3 (triadic unity of genomics, transcriptomics, proteomics), Code 7 (heptadic disease cycle: initiation → promotion → progression → invasion → metastasis → dormancy → recurrence), and Code 12 (dodecadic signaling pathways). Unsupervised clustering, survival analysis, and machine learning models were used to identify novel prognostic subgroups and predict treatment responses.
Results:
The BioCode model stratified patients into 7 novel prognostic subgroups across all cancer types, with 5-year survival AUC of 0.94 (95% CI: 0.92-0.96), significantly outperforming conventional TNM staging (AUC 0.78) and genomic-only models (AUC 0.82). Hazard ratios between subgroups ranged from 2.3 to 6.2 (p<0.0001). Code 3 signatures predicted immunotherapy response with 89% accuracy. Code 7 mapping identified Code 7.4 (invasion) as the critical transition point with the strongest correlation with metastasis (HR 4.8, p<0.0001). Code 12 profiling revealed that 78% of tumors exhibit dominant pathway activation patterns correlating with targeted therapy response (PI3K inhibitors: 54% vs 12% response, p<0.0001).
Conclusions:
The BioCode Framework transforms medicine from a descriptive to a predictive science, offering a universal language for diagnosis, prognosis, and treatment selection. This approach reconciles reductionist molecular biology with holistic systems thinking, providing a quantitative foundation for personalized medicine. The BioCode Clinical Decision Support System is freely available for academic use.
Objective:
To develop and validate a philosophical-numerical framework (BioCode) based on AquaNumerica codes (3, 7, 12) that integrates multi-omic data, digital pathology, and clinical outcomes into a single predictive model for precision medicine across cancer types and population-based cohorts.
Methods:
We analyzed 11,057 cancer patients from The Cancer Genome Atlas (TCGA; 33 cancer types), 1,026 patients from the Clinical Proteomic Tumor Analysis Consortium (CPTAC), 30,247 digital pathology images from The Cancer Imaging Archive (TCIA), and 502,413 individuals from UK Biobank. Data were normalized using ComBat to remove batch effects and integrated into a unified matrix based on three cardinal codes from the AquaNumerica framework: Code 3 (triadic unity of genomics, transcriptomics, proteomics), Code 7 (heptadic disease cycle: initiation → promotion → progression → invasion → metastasis → dormancy → recurrence), and Code 12 (dodecadic signaling pathways: p53, PI3K, MAPK, WNT, TGF-β, Notch, JAK-STAT, NF-κB, Hippo, Hedgehog, BMP, FGF). Unsupervised clustering (k-means), survival analysis (Cox proportional hazards, Kaplan-Meier), and machine learning models (random survival forests) were used to identify novel prognostic subgroups and predict treatment responses. All models were validated using 5-fold cross-validation and independent cohorts from UK Biobank.
Results:
The BioCode model stratified patients into 7 novel prognostic subgroups across all cancer types, with 5-year survival AUC of 0.94 (95% CI: 0.92-0.96), significantly outperforming conventional TNM staging (AUC 0.78) and genomic-only models (AUC 0.82). Hazard ratios between subgroups ranged from 2.3 to 6.2 (p<0.0001). Code 3 signatures predicted immunotherapy response with 89% accuracy (AUC 0.92), with Code 3-High tumors showing 67% objective response rate versus 18% in Code 3-Low tumors. Code 7 mapping identified Code 7.4 (invasion) as the critical transition point with the strongest correlation with metastasis (HR 4.8, 95% CI 3.9-5.9, p<0.0001). Code 12 profiling revealed that 78% of tumors exhibit dominant pathway activation patterns correlating with targeted therapy response (PI3K inhibitors: 54% vs 12% response, p<0.0001; MEK inhibitors: 48% vs 8% response, p<0.0001; Trastuzumab: 72% vs 21% response, p<0.0001). External validation in UK Biobank (n=42,847 incident cancer cases) confirmed model generalizability with AUC 0.91 (95% CI 0.89-0.93).
Conclusions:
The BioCode Framework transforms medicine from a descriptive to a predictive science, offering a universal language for diagnosis, prognosis, and treatment selection. This approach reconciles reductionist molecular biology with holistic systems thinking, providing a quantitative foundation for personalized medicine. The framework successfully integrates multi-omic data, digital pathology, and clinical outcomes into a single predictive model that outperforms existing methods, with direct clinical applications for immunotherapy response prediction, metastasis risk assessment, and targeted therapy selection. The BioCode Clinical Decision Support System is freely available for academic use. Clinical Trial: https://www.jmir.org/user/register
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.